8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
People assigned to a diet, food or program and measured.
2016 / Two randomized controlled trials
Two randomized controlled trials evaluated the effects of flavonoid interventions on serum BDNF and cognitive function. In Trial 1, an 18-week intervention with high-flavonoid fruit and vegetables, but not low-flavonoid, induced significant improvements in cognitive performance and increases in serum BDNF (p < 0.001). In Trial 2, a high-flavanol cocoa drink (494 mg total flavanols) for 12 weeks also significantly increased serum BDNF (p < 0.001), which correlated with improvements in global cognitive performance.
Neshatdoust S, Saunders C, Castle SM, et al. Nutr Healthy Aging, 2016. PMID 28035345
2015 / Randomized controlled trial
A 4-week randomized, double-blind, placebo-controlled trial assessed the effects of gluten and milk on gut permeability and behavior in children with autism spectrum disorders. Intestinal permeability was evaluated using the lactulose:mannitol ratio, alongside standardized behavioral scores and gastrointestinal symptoms. Neither intestinal permeability nor behavioral metrics differed between groups receiving gluten and dairy versus placebo, and observed variations were small and not clinically meaningful.
Navarro F, Pearson DA, Fatheree N, et al. Nutr Neurosci, 2015. PMID 24564346
2015 / Randomized controlled trial (secondary analysis)
In a 6-month trial, 86 women aged 70-80 years with probable mild cognitive impairment were randomly assigned to twice-weekly aerobic training (AT), resistance training (RT), or balance and tone training (BAT, control). Compared with BAT, AT significantly improved left, right, and total hippocampal volumes (p<=0.03). After adjusting for baseline cognitive function and experimental group, increased left hippocampal volume was independently associated with reduced verbal memory and learning performance indexed by loss after interference (r=0.42, p=0.03).
ten Brinke LF, Bolandzadeh N, Nagamatsu LS, et al. Br J Sports Med, 2015. PMID 24711660
2015 / Double-blind, placebo-controlled, randomized clinical trial
A 2-site trial randomized 196 adults with DSM-IV major depressive disorder to 8 weeks of EPA-enriched omega-3 (1,000 mg/d), DHA-enriched omega-3 (1,000 mg/d), or placebo. All three groups exhibited statistically significant improvements in HDRS-17, QIDS-SR-16, and CGI-S scores (P < .05), but neither active preparation separated significantly from placebo (P > .05). Response rates were 40%-50% and remission rates were approximately 30% across all treatments without significant differences between groups.
Mischoulon D, Nierenberg AA, Schettler PJ, et al. J Clin Psychiatry, 2015. PMID 25272149
2015 / Randomized controlled trial
Thirty-one patients with Alzheimer's disease and 31 age-similar controls received a carotenoid formulation (10 mg meso-zeaxanthin, 10 mg lutein, 2 mg zeaxanthin) or sunflower oil placebo for 6 months. Active supplementation significantly raised serum carotenoid concentrations and macular pigment (p < 0.001 for all) and improved contrast sensitivity (p = 0.039). Cognitive function outcomes showed no significant changes in any measured variable (p > 0.05 for all).
Nolan JM, Loskutova E, Howard A, et al. J Alzheimers Dis, 2015. PMID 25408222
2015 / Randomized placebo-controlled trial
In an initial evaluation of 102 young healthy subjects, macular pigment optical density (MPOD) was positively correlated with temporal contrast sensitivity function (tCSF). In a follow-up, 69 subjects were randomized to receive a placebo (n=15) or one of two lutein and zeaxanthin supplements (n=54) for 4 months. Neither MPOD nor tCSF changed in the placebo group, but both improved significantly following supplementation.
Bovier ER, Hammond BR Arch Biochem Biophys, 2015. PMID 25483230
2015 / Randomized double-blind placebo-controlled trial
A four-week randomized, double-blind, placebo-controlled trial tested crocin tablets (30 mg/day) alongside SSRI therapy in 40 patients with major depressive disorder. The crocin group demonstrated significantly greater decreases in Beck Depression Inventory (17.6 vs. 6.15), Beck Anxiety Inventory (12.7 vs. 2.6), and General Health Questionnaire scores (17.2 vs. 10.3) compared to placebo (p < 0.0001). Limitations included a brief intervention period, modest sample size, and dependence on self-reported evaluations.
Talaei A, Hassanpour Moghadam M, Sajadi Tabassi SA, et al. J Affect Disord, 2015. PMID 25484177
2015 / Randomized clinical trial
Older adults with moderate sleep disturbances were randomized to a 6-week mindful awareness practices (MAPs, n=24) or sleep hygiene education (SHE, n=25) intervention. In intent-to-treat analysis, the MAPs group showed significant improvement on the PSQI compared to the SHE group (between-group mean difference 1.8 [95% CI, 0.6-2.9], effect size 0.89), with postintervention scores of 7.4 (1.9) vs 9.1 (2.0). MAPs also led to significant improvements over SHE in insomnia symptoms, depression symptoms, fatigue interference, and fatigue severity (P < .05 for all), while anxiety, stress, and NF-κB showed no between-group differences.
Black DS, O'Reilly GA, Olmstead R, et al. JAMA Intern Med, 2015. PMID 25686304
2015 / Randomized crossover trial
A randomized crossover trial evaluated 83 migraine patients who followed a low-lipid diet or a normal-lipid diet for 3 months each. Migraine attack frequency dropped significantly more on the low-lipid diet (2.9 +/- 3.7 vs. 6.8 +/- 7.5 attacks, p < 0.001). Attack severity was also lower on the low-lipid diet (1.2 +/- 0.9 vs. 1.7 +/- 0.9, p < 0.01).
Ferrara LA, Pacioni D, Di Fronzo V, et al. Nutr Metab Cardiovasc Dis, 2015. PMID 25698152
2015 / Double-blind cross-over trial
In a double-blind cross-over study, the sleep of 22 young and 24 middle-aged adults was recorded using polysomnography under placebo and caffeine conditions (200 mg and 400 mg). Compared to placebo, caffeine increased sleep latency, shortened total sleep duration, and reduced sleep efficiency, with effects at the 400 mg dose being more pronounced in middle-aged adults. In both age groups, caffeine dose-dependently increased relative stage 1 sleep and reduced absolute and relative slow wave sleep as well as absolute rapid eye movement sleep. The 400 mg dose increased absolute stage 1 sleep in young adults but decreased absolute stage 2 sleep in middle-aged adults.
Robillard R, Bouchard M, Cartier A, et al. J Psychopharmacol, 2015. PMID 25759402
2015 / Randomized, placebo-controlled trial
A 6-month randomized, placebo-controlled trial evaluated 1.5 g of omega-3 fatty acid supplements versus placebo in 38 children aged 2 to 5 years with autism spectrum disorder (ASD). There was no significant difference between groups in the 0- to 24-week change in PDDBI autism composite scores (p = 0.5), adaptive function (p = 0.09), or language gains (p = 0.6). A significant group by week interaction was observed for the BASC-2 externalizing problem score, with participants in the omega-3 group showing worsening scores (p = 0.02). Omega-3s were relatively well tolerated, and changes in cytokine profiles did not significantly correlate with treatment response.
Mankad D, Dupuis A, Smile S, et al. Mol Autism, 2015. PMID 25798215
2015 / Randomized crossover trial
Sixteen male team-sport athletes consumed nitrate-rich or nitrate-depleted beetroot juice for 7 days in a randomized crossover study before undergoing an intermittent sprint test with concurrent cognitive tasks. Total sprint work was greater with nitrate supplementation (123 ± 19 kJ) than with placebo (119 ± 17 kJ; P < 0.05). In addition, cognitive reaction time in the second half of testing improved with nitrate juice compared to placebo (P < 0.05), with no difference observed in response accuracy.
Thompson C, Wylie LJ, Fulford J, et al. Eur J Appl Physiol, 2015. PMID 25846114
2015 / Randomized controlled trial
An 8-week randomized double-blind placebo-controlled trial evaluated 43 adult patients with major depressive disorder receiving citalopram with either vitamin C (n=21) or placebo (n=22). Although depression scores declined in both arms, the difference between groups was not statistically significant (P = .5). Remission rates, response rates, and adverse effects showed no significant differences between the vitamin C and placebo groups.
Sahraian A, Ghanizadeh A, Kazemeini F Trials, 2015. PMID 25873303
2015 / Randomized controlled trial
In a six-week trial, older adults aged over 60 consumed either two cups of frozen blueberries daily or a carrot-based control beverage. Compared with the control drink, blueberry supplementation led to significant reductions in step errors during a challenging dual-task adaptive gait assessment. Within the blueberry cohort, participants also showed significant gains in usual walking pace, single-task step accuracy, and dual-task movement speed.
Schrager MA, Hilton J, Gould R, et al. Appl Physiol Nutr Metab, 2015. PMID 25909473
2015 / Interventional study
An 8-week alternate day fasting (ADF) protocol was tested in 59 obese subjects, with food provided on fast days. Body weight decreased by 4.2 ± 0.3% (P < 0.0001). Adverse events reported included constipation (17%), water retention (2%), dizziness (<20%), general weakness (<15%), and non-significantly increased bad breath (14% to 29%). Depression and binge eating decreased (P < 0.01), restrictive eating increased (P < 0.01), body image improved (P < 0.01), and purgative behavior and fear of fatness were unchanged.
Hoddy KK, Kroeger CM, Trepanowski JF, et al. Nutr J, 2015. PMID 25943396
2015 / 12-week double-blind placebo-controlled randomized trial
A 12-week double-blind, placebo-controlled trial evaluated maca root (3.0 g/day) in 45 female outpatients with remitted depression and SSRI/SNRI-induced sexual dysfunction, with 42 eligible for modified intent-to-treat analysis. Remission rates at the end of treatment were higher with maca than placebo for an ASEX score ≤ 10 (9.5% vs. 4.8%), an MGH-SFQ score ≤ 12 (30.0% vs. 20.0%), and an MGH-SFQ score ≤ 8 (9.5% vs. 5.0%). Higher remission rates with maca compared to placebo were associated with postmenopausal status. Maca was reported to be well tolerated.
Dording CM, Schettler PJ, Dalton ED, et al. Evid Based Complement Alternat Med, 2015. PMID 25954318
2015 / Randomized controlled trial
In a randomized, placebo-controlled trial, 40 healthy adults drank either placebo or 450 mL of nitrate-rich beetroot juice (~5.5 mmol nitrate). Near-infrared spectroscopy monitored prefrontal cortex cerebral blood flow throughout 54 minutes of cognitive testing following a 90-minute absorption period. Beetroot juice modulated cerebral hemodynamics across tasks and improved performance on the serial 3s subtraction task.
Wightman EL, Haskell-Ramsay CF, Thompson KG, et al. Physiol Behav, 2015. PMID 26037632
2015 / Comparative crossover trial
Seventeen Japanese adult females viewed a kiwifruit orchard landscape or a building site (control) for 10 minutes. Compared with viewing the building site, viewing the orchard landscape resulted in a significant increase in parasympathetic activity, a marginally significant decrease in heart rate, a significant increase in 'comfortable', 'relaxed', and 'natural' feelings, and a significant improvement in mood states.
Igarashi M, Miwa M, Ikei H, et al. Int J Environ Res Public Health, 2015. PMID 26110331
2015 / Randomized controlled trial
In an ancillary trial within AREDS2, 3,501 older adults at risk for late age-related macular degeneration were randomized to receive omega-3 polyunsaturated fatty acids, lutein/zeaxanthin, both, or placebo. Over five years, yearly change in composite cognitive test scores did not differ between the fatty acid group (-0.19; 99% CI, -0.25 to -0.13) and control (-0.18; 99% CI, -0.24 to -0.12; P = .63). Similarly, lutein/zeaxanthin showed no difference compared to placebo (P = .66).
Chew EY, Clemons TE, Agrón E, et al. JAMA, 2015. PMID 26305649
2015 / Randomised, double-blind, placebo-controlled, parallel-groups study
In a randomised, double-blind, placebo-controlled study, 60 adults aged 18 to 30 years were given resveratrol or placebo for 28 days. Resveratrol modulated cerebral blood flow (CBF) parameters on day 1 as assessed by near-IR spectroscopy and significantly lowered subjective ratings of fatigue across the entire 28 days. Cognitive effects were limited to more accurate but slower serial subtraction performance on day 1, and improved 3-Back task accuracy before dose on day 28. Resveratrol significantly increased diastolic blood pressure on day 28 and resulted in higher resveratrol metabolite levels on day 28 compared with day 1.
Wightman EL, Haskell-Ramsay CF, Reay JL, et al. Br J Nutr, 2015. PMID 26344014
2015 / Randomized, double-blind, placebo-controlled trial
In a randomized trial, 42 high school students received either 500 mg per day of vitamin C or a placebo for 14 days. Supplementation significantly decreased anxiety levels on the Beck Anxiety Inventory and increased plasma vitamin C concentrations compared to placebo. A significant difference in mean heart rate was also observed between groups.
de Oliveira IJ, de Souza VV, Motta V, et al. Pak J Biol Sci, 2015. PMID 26353411
2015 / Randomized controlled trial
Twenty-four elderly patients diagnosed with depression were randomly divided into an experimental group practicing Nordic walking and a control group practicing normal walking. Both groups exercised for 50 minutes per day, three times per week for eight weeks. Both groups showed significant improvements in depression over time, with significant differences over time between groups for depression, sleep, and skeletal muscle mass.
Park SD, Yu SH J Phys Ther Sci, 2015. PMID 26357429
2015 / Randomized, double-blind, placebo-controlled phase 2 trial
In a 52-week phase 2 trial, 119 participants with mild to moderate Alzheimer disease were randomized to placebo or oral resveratrol (dose-escalated from 500 mg daily to 1,000 mg twice daily). Resveratrol and its major metabolites penetrated the blood-brain barrier. The most frequent adverse events were nausea, diarrhea, and weight loss. CSF Aβ40 and plasma Aβ40 levels declined more in the placebo group than in the resveratrol group, producing a significant difference at week 52, while brain volume loss was increased with resveratrol compared to placebo.
Turner RS, Thomas RG, Craft S, et al. Neurology, 2015. PMID 26362286
2015 / Interventional study
College students (N=122) self-monitored their eating behaviors for 96 hours, including a 24-hour fasting period, to examine the impact of short-term fasting on pathological eating patterns. Participants did not demonstrate significant increases in disordered eating behaviors following the fast, including objective binge episodes, self-defined excessive eating, or compensatory behavior use. However, baseline disinhibition predicted excessive eating and objective binge episodes both before and after fasting.
Schaumberg K, Anderson DA, Reilly EE, et al. Eat Behav, 2015. PMID 26431904